RIGGS RORY B
Insider CIK 1016835 · ITCI Director · CBUS Chief Executive Officer, Director, 10% owner · RPRX Director · FGEN Director
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| CBUS Cibus, Inc. | A Award deriv | 2026-06-02 | 2026-06-04 | 77,586 | — | $0 | 77,586 | SEC↗ |
| CBUS Cibus, Inc. | A Award | 2026-01-29 | 2026-02-02 | 333,333 | $1.50 | $500.0K | 14,916,640 | SEC↗ |
| CBUS Cibus, Inc. | X Exercise deriv | 2025-06-09 | 2025-06-11 | 50,000 | — | $0 | 0 | SEC↗ |
| CBUS Cibus, Inc. | X Exercise deriv | 2025-06-09 | 2025-06-11 | 4,000,000 | — | $0 | 0 | SEC↗ |
| CBUS Cibus, Inc. | X Exercise | 2025-06-09 | 2025-06-11 | 50,000 | $0.01 | $500 | 14,583,307 | SEC↗ |
| CBUS Cibus, Inc. | X Exercise | 2025-06-09 | 2025-06-11 | 4,000,000 | — | $0 | 14,533,307 | SEC↗ |
| CBUS Cibus, Inc. | A Award | 2025-06-05 | 2025-06-10 | 5,714,286 | $1.75 | $10.00M | 10,533,307 | SEC↗ |
| CBUS Cibus, Inc. | A Award deriv | 2025-05-22 | 2025-05-27 | 39,301 | — | $0 | 39,301 | SEC↗ |
| ITCI Intra-Cellular Therapies, | D To issuer deriv | 2025-04-02 | 2025-04-02 | 20,000 | — | $0 | 0 | SEC↗ |
| ITCI Intra-Cellular Therapies, | D To issuer deriv | 2025-04-02 | 2025-04-02 | 20,000 | — | $0 | 0 | SEC↗ |
| ITCI Intra-Cellular Therapies, | D To issuer deriv | 2025-04-02 | 2025-04-02 | 2,951 | — | $0 | 0 | SEC↗ |
| ITCI Intra-Cellular Therapies, | D To issuer deriv | 2025-04-02 | 2025-04-02 | 20,000 | — | $0 | 0 | SEC↗ |
| ITCI Intra-Cellular Therapies, | D To issuer deriv | 2025-04-02 | 2025-04-02 | 20,000 | — | $0 | 0 | SEC↗ |
| ITCI Intra-Cellular Therapies, | D To issuer deriv | 2025-04-02 | 2025-04-02 | 16,757 | — | $0 | 0 | SEC↗ |
| ITCI Intra-Cellular Therapies, | D To issuer deriv | 2025-04-02 | 2025-04-02 | 4,322 | — | $0 | 0 | SEC↗ |
| ITCI Intra-Cellular Therapies, | D To issuer deriv | 2025-04-02 | 2025-04-02 | 7,009 | — | $0 | 0 | SEC↗ |
| ITCI Intra-Cellular Therapies, | D To issuer | 2025-04-02 | 2025-04-02 | 131,512 | $132.00 | $17.36M | 0 | SEC↗ |
| CBUS Cibus, Inc. | A Award deriv | 2025-01-21 | 2025-01-23 | 4,000,000 | $2.50 | $10.00M | 4,000,000 | SEC↗ |
| CBUS Cibus, Inc. | A Award deriv | 2025-01-21 | 2025-01-23 | 4,000,000 | — | $0 | 4,000,000 | SEC↗ |
| CBUS Cibus, Inc. | C Conversion deriv | 2024-12-31 | 2025-01-10 | 1,388,084 | — | $0 | 0 | SEC↗ |
| ITCI Intra-Cellular Therapies, | A Award | 2024-12-31 | 2025-01-03 | 215 | $83.52 | $18.0K | 131,512 | SEC↗ |
| CBUS Cibus, Inc. | C Conversion | 2024-12-31 | 2025-01-10 | 1,388,084 | — | $0 | 4,839,912 | SEC↗ |
| CBUS Cibus, Inc. | C Conversion | 2024-12-31 | 2025-01-10 | 1,388,084 | — | $0 | 0 | SEC↗ |
| ITCI Intra-Cellular Therapies, | A Award | 2024-09-30 | 2024-10-02 | 246 | $73.17 | $18.0K | 117,108 | SEC↗ |
| CBUS Cibus, Inc. | A Award | 2024-09-18 | 2024-09-20 | 250,000 | $4.00 | $1.00M | 3,451,828 | SEC↗ |
| ITCI Intra-Cellular Therapies, | A Award | 2024-06-28 | 2024-07-02 | 262 | $68.49 | $17.9K | 116,862 | SEC↗ |
| ITCI Intra-Cellular Therapies, | M Exercise deriv | 2024-06-24 | 2024-06-25 | 20,000 | — | $0 | 0 | SEC↗ |
| ITCI Intra-Cellular Therapies, | S Sale | 2024-06-24 | 2024-06-25 | 4,462 | $75.57 | $337.2K | 116,600 | SEC↗ |
| ITCI Intra-Cellular Therapies, | M Exercise | 2024-06-24 | 2024-06-25 | 20,000 | $16.86 | $337.2K | 121,062 | SEC↗ |
| ITCI Intra-Cellular Therapies, | M Exercise deriv | 2024-06-23 | 2024-06-25 | 1,567 | — | $0 | 0 | SEC↗ |
| ITCI Intra-Cellular Therapies, | M Exercise | 2024-06-23 | 2024-06-25 | 1,567 | — | $0 | 101,062 | SEC↗ |
| ITCI Intra-Cellular Therapies, | A Award deriv | 2024-06-14 | 2024-06-18 | 4,322 | — | $0 | 4,322 | SEC↗ |
| ITCI Intra-Cellular Therapies, | A Award deriv | 2024-06-14 | 2024-06-18 | 2,951 | — | $0 | 2,951 | SEC↗ |
| CBUS Cibus, Inc. | A Award deriv | 2024-06-11 | 2024-06-14 | 98,040 | — | $0 | 98,040 | SEC↗ |
| CBUS Cibus, Inc. | A Award | 2024-06-11 | 2024-06-14 | 98,040 | $10.20 | $1.00M | 3,201,828 | SEC↗ |
| ITCI Intra-Cellular Therapies, | A Award | 2024-03-31 | 2024-04-02 | 260 | $69.20 | $18.0K | 99,495 | SEC↗ |
| ITCI Intra-Cellular Therapies, | M Exercise deriv | 2024-03-20 | 2024-03-22 | 20,000 | — | $0 | 0 | SEC↗ |
| ITCI Intra-Cellular Therapies, | M Exercise | 2024-03-20 | 2024-03-22 | 20,000 | $18.56 | $371.2K | 99,235 | SEC↗ |
| RPRX Royalty Pharma plc | C Conversion deriv | 2024-02-20 | 2024-02-22 | 30,000 | — | $0 | 270,000 | SEC↗ |
| RPRX Royalty Pharma plc | C Conversion | 2024-02-20 | 2024-02-22 | 300,000 | — | $0 | 320,099 | SEC↗ |
| RPRX Royalty Pharma plc | S Sale | 2024-01-04 | 2024-01-04 | 35,702 | $27.55 | $983.6K | 20,099 | SEC↗ |
| RPRX Royalty Pharma plc | S Sale | 2024-01-03 | 2024-01-04 | 199,098 | $27.79 | $5.53M | 55,801 | SEC↗ |
| RPRX Royalty Pharma plc | S Sale | 2024-01-02 | 2024-01-04 | 235,200 | $28.52 | $6.71M | 254,899 | SEC↗ |
| ITCI Intra-Cellular Therapies, | A Award | 2023-12-31 | 2024-01-03 | 251 | $71.62 | $18.0K | 79,235 | SEC↗ |
| CBUS Cibus, Inc. | J Other deriv | 2023-12-29 | 2024-01-03 | 1,505,967 | — | $0 | 2,867,193 | SEC↗ |
| CBUS Cibus, Inc. | C Conversion deriv | 2023-12-29 | 2024-01-03 | 1,500,000 | — | $0 | 1,367,193 | SEC↗ |
| CBUS Cibus, Inc. | C Conversion | 2023-12-29 | 2024-01-03 | 1,500,000 | — | $0 | 1,367,193 | SEC↗ |
| CBUS Cibus, Inc. | C Conversion | 2023-12-29 | 2024-01-03 | 1,500,000 | — | $0 | 3,103,788 | SEC↗ |
| CBUS Cibus, Inc. | J Other | 2023-12-29 | 2024-01-03 | 1,505,967 | — | $0 | 2,867,193 | SEC↗ |
| CBUS Cibus, Inc. | J Other deriv | 2023-12-12 | 2023-12-14 | 50,000 | $10.57 | $528.5K | 50,000 | SEC↗ |
| CBUS Cibus, Inc. | P Buy | 2023-12-12 | 2023-12-14 | 517,107 | $10.58 | $5.47M | 1,622,495 | SEC↗ |
| RPRX Royalty Pharma plc | C Conversion deriv | 2023-11-13 | 2023-11-14 | 47,559 | — | $0 | 300,000 | SEC↗ |
| RPRX Royalty Pharma plc | C Conversion | 2023-11-13 | 2023-11-14 | 475,590 | — | $0 | 490,099 | SEC↗ |
| ITCI Intra-Cellular Therapies, | A Award | 2023-09-30 | 2023-10-02 | 345 | $52.09 | $18.0K | 78,984 | SEC↗ |
| CBUS Cibus, Inc. | J Other | 2023-09-27 | 2023-12-14 | 39,476 | — | $0 | 1,105,388 | SEC↗ |
| RPRX Royalty Pharma plc | G Gift deriv | 2023-08-08 | 2023-08-08 | 6,500 | — | $0 | 347,559 | SEC↗ |
| ITCI Intra-Cellular Therapies, | A Award | 2023-06-30 | 2023-07-05 | 279 | $63.32 | $17.7K | 78,639 | SEC↗ |
| ITCI Intra-Cellular Therapies, | A Award deriv | 2023-06-23 | 2023-06-27 | 7,009 | — | $0 | 7,009 | SEC↗ |
| ITCI Intra-Cellular Therapies, | A Award deriv | 2023-06-23 | 2023-06-27 | 1,567 | — | $0 | 1,567 | SEC↗ |
| RPRX Royalty Pharma plc | A Award | 2023-06-23 | 2023-06-26 | 7,747 | — | $0 | 14,509 | SEC↗ |
| CBUS Cibus, Inc. | P Buy | 2023-06-01 | 2023-06-02 | 1,000 | $31.50 | $31.5K | 1,154,464 | SEC↗ |
| CBUS Cibus, Inc. | A Award deriv | 2023-05-31 | 2023-06-02 | 1,505,967 | — | $0 | 2,888,084 | SEC↗ |
| CBUS Cibus, Inc. | A Award deriv | 2023-05-31 | 2023-06-02 | 1,361,226 | — | $0 | 1,361,226 | SEC↗ |
| CBUS Cibus, Inc. | A Award deriv | 2023-05-31 | 2023-06-02 | 20,891 | — | $0 | 1,382,117 | SEC↗ |
| CBUS Cibus, Inc. | A Award | 2023-05-31 | 2023-06-02 | 2,916 | — | $0 | 851,578 | SEC↗ |
| CBUS Cibus, Inc. | A Award | 2023-05-31 | 2023-06-02 | 20,891 | — | $0 | 1,382,117 | SEC↗ |
| CBUS Cibus, Inc. | A Award | 2023-05-31 | 2023-06-02 | 1,505,967 | — | $0 | 2,888,084 | SEC↗ |
| CBUS Cibus, Inc. | A Award | 2023-05-31 | 2023-06-02 | 848,662 | — | $0 | 848,662 | SEC↗ |
| CBUS Cibus, Inc. | A Award | 2023-05-31 | 2023-06-02 | 167,992 | — | $0 | 1,153,464 | SEC↗ |
| CBUS Cibus, Inc. | A Award | 2023-05-31 | 2023-06-02 | 9,600 | — | $0 | 985,472 | SEC↗ |
| CBUS Cibus, Inc. | A Award | 2023-05-31 | 2023-06-02 | 5,401 | — | $0 | 975,872 | SEC↗ |
| CBUS Cibus, Inc. | A Award | 2023-05-31 | 2023-06-02 | 118,893 | — | $0 | 970,471 | SEC↗ |
| CBUS Cibus, Inc. | A Award | 2023-05-31 | 2023-06-02 | 1,361,226 | — | $0 | 1,361,226 | SEC↗ |
| RPRX Royalty Pharma plc | S Sale | 2023-05-22 | 2023-05-22 | 1,750,000 | $32.82 | $57.44M | 6,762 | SEC↗ |
| RPRX Royalty Pharma plc | C Conversion deriv | 2023-05-09 | 2023-05-12 | 30,000 | — | $0 | 354,059 | SEC↗ |
| RPRX Royalty Pharma plc | C Conversion | 2023-05-09 | 2023-05-12 | 300,000 | — | $0 | 1,756,762 | SEC↗ |
| ITCI Intra-Cellular Therapies, | A Award | 2023-03-31 | 2023-04-04 | 313 | $54.15 | $16.9K | 78,360 | SEC↗ |
| RPRX Royalty Pharma plc | S Sale | 2023-03-30 | 2023-03-30 | 130,024 | $36.26 | $4.71M | 1,456,762 | SEC↗ |
| RPRX Royalty Pharma plc | S Sale | 2023-03-29 | 2023-03-30 | 9,926 | $36.95 | $366.8K | 1,586,786 | SEC↗ |
| RPRX Royalty Pharma plc | C Conversion deriv | 2023-02-17 | 2023-02-17 | 150,000 | — | $0 | 384,059 | SEC↗ |
| RPRX Royalty Pharma plc | C Conversion | 2023-02-17 | 2023-02-17 | 1,500,000 | — | $0 | 1,596,712 | SEC↗ |
| ITCI Intra-Cellular Therapies, | A Award | 2022-12-30 | 2023-01-03 | 321 | $52.92 | $17.0K | 78,047 | SEC↗ |
| RPRX Royalty Pharma plc | S Sale | 2022-12-09 | 2022-12-13 | 19,990 | $42.07 | $841.0K | 136,722 | SEC↗ |
| RPRX Royalty Pharma plc | S Sale | 2022-11-17 | 2022-11-21 | 120,000 | $42.33 | $5.08M | 156,712 | SEC↗ |
| ITCI Intra-Cellular Therapies, | A Award | 2022-09-30 | 2022-10-04 | 365 | $46.53 | $17.0K | 77,726 | SEC↗ |
| RPRX Royalty Pharma plc | S Sale | 2022-09-15 | 2022-09-15 | 52,025 | $42.21 | $2.20M | 276,712 | SEC↗ |
| RPRX Royalty Pharma plc | S Sale | 2022-09-14 | 2022-09-15 | 47,975 | $42.41 | $2.03M | 328,737 | SEC↗ |
| RPRX Royalty Pharma plc | S Sale | 2022-08-09 | 2022-08-11 | 45,000 | $43.73 | $1.97M | 376,712 | SEC↗ |
| ITCI Intra-Cellular Therapies, | A Award | 2022-06-30 | 2022-07-05 | 289 | $57.08 | $16.5K | 77,361 | SEC↗ |
| RPRX Royalty Pharma plc | S Sale | 2022-06-29 | 2022-06-29 | 30,000 | $42.17 | $1.27M | 421,712 | SEC↗ |
| ITCI Intra-Cellular Therapies, | A Award deriv | 2022-06-09 | 2022-06-13 | 16,757 | — | $0 | 16,757 | SEC↗ |
| RPRX Royalty Pharma plc | S Sale | 2022-05-20 | 2022-05-23 | 123,696 | $39.28 | $4.86M | 451,712 | SEC↗ |
| RPRX Royalty Pharma plc | S Sale | 2022-05-19 | 2022-05-23 | 26,304 | $40.09 | $1.05M | 575,408 | SEC↗ |
| ITCI Intra-Cellular Therapies, | A Award | 2022-03-31 | 2022-04-04 | 257 | $61.19 | $15.7K | 77,072 | SEC↗ |
| RPRX Royalty Pharma plc | S Sale | 2022-03-29 | 2022-03-30 | 60,000 | $38.59 | $2.32M | 601,712 | SEC↗ |
| RPRX Royalty Pharma plc | S Sale | 2022-03-21 | 2022-03-21 | 25,545 | $39.05 | $997.5K | 0 | SEC↗ |
| RPRX Royalty Pharma plc | S Sale | 2022-03-21 | 2022-03-21 | 14,322 | $39.05 | $559.3K | 0 | SEC↗ |
| ITCI Intra-Cellular Therapies, | S Sale | 2022-03-18 | 2022-03-18 | 15,736 | $61.35 | $965.4K | 0 | SEC↗ |
| ITCI Intra-Cellular Therapies, | S Sale | 2022-03-18 | 2022-03-18 | 4,901 | $60.63 | $297.1K | 15,736 | SEC↗ |
| RPRX Royalty Pharma plc | S Sale | 2022-03-18 | 2022-03-21 | 56,181 | $39.77 | $2.23M | 85,187 | SEC↗ |
| RPRX Royalty Pharma plc | S Sale | 2022-03-18 | 2022-03-21 | 26,238 | $39.38 | $1.03M | 14,322 | SEC↗ |
| RPRX Royalty Pharma plc | S Sale | 2022-03-18 | 2022-03-21 | 46,803 | $39.38 | $1.84M | 25,545 | SEC↗ |
| ITCI Intra-Cellular Therapies, | S Sale | 2022-03-17 | 2022-03-18 | 114,912 | $60.41 | $6.94M | 20,637 | SEC↗ |
| ITCI Intra-Cellular Therapies, | S Sale | 2022-03-17 | 2022-03-18 | 26,587 | $59.99 | $1.59M | 135,549 | SEC↗ |
| RPRX Royalty Pharma plc | J Other | 2022-03-17 | 2022-03-21 | 531,684 | — | $0 | 141,368 | SEC↗ |
| RPRX Royalty Pharma plc | J Other | 2022-03-17 | 2022-03-21 | 1,075,178 | — | $0 | 40,560 | SEC↗ |
| RPRX Royalty Pharma plc | J Other | 2022-03-17 | 2022-03-21 | 229,626 | — | $0 | 72,348 | SEC↗ |
| RPRX Royalty Pharma plc | J Other | 2022-03-17 | 2022-03-21 | 64,067 | — | $0 | 661,712 | SEC↗ |
| RPRX Royalty Pharma plc | J Other | 2022-03-17 | 2022-03-21 | 4,897 | — | $0 | 597,645 | SEC↗ |
| ITCI Intra-Cellular Therapies, | S Sale | 2022-03-16 | 2022-03-18 | 43,848 | $59.53 | $2.61M | 162,136 | SEC↗ |
| ITCI Intra-Cellular Therapies, | S Sale | 2022-03-16 | 2022-03-18 | 20,686 | $58.72 | $1.21M | 205,984 | SEC↗ |
| ITCI Intra-Cellular Therapies, | A Award | 2021-12-31 | 2022-01-04 | 300 | $52.34 | $15.7K | 76,815 | SEC↗ |
| RPRX Royalty Pharma plc | S Sale | 2021-12-29 | 2021-12-30 | 75,000 | $40.00 | $3.00M | 592,748 | SEC↗ |
| RPRX Royalty Pharma plc | J Other | 2021-12-28 | 2021-12-30 | 407,400 | — | $0 | 708,245 | SEC↗ |
| RPRX Royalty Pharma plc | S Sale | 2021-12-28 | 2021-12-30 | 35,193 | $40.21 | $1.42M | 673,052 | SEC↗ |
| RPRX Royalty Pharma plc | S Sale | 2021-12-28 | 2021-12-30 | 26,677 | $40.21 | $1.07M | 1,115,738 | SEC↗ |
| RPRX Royalty Pharma plc | S Sale | 2021-12-28 | 2021-12-30 | 47,578 | $40.21 | $1.91M | 301,974 | SEC↗ |
| RPRX Royalty Pharma plc | J Other | 2021-12-28 | 2021-12-30 | 707,155 | — | $0 | 1,142,415 | SEC↗ |
| RPRX Royalty Pharma plc | J Other | 2021-12-28 | 2021-12-30 | 150,997 | — | $0 | 349,552 | SEC↗ |
| RPRX Royalty Pharma plc | J Other | 2021-12-28 | 2021-12-30 | 42,138 | — | $0 | 667,748 | SEC↗ |
| RPRX Royalty Pharma plc | J Other | 2021-12-28 | 2021-12-30 | 3,212 | — | $0 | 625,610 | SEC↗ |
| RPRX Royalty Pharma plc | S Sale | 2021-11-17 | 2021-11-18 | 31,341 | $42.33 | $1.33M | 1,115,645 | SEC↗ |
| RPRX Royalty Pharma plc | S Sale | 2021-11-17 | 2021-11-18 | 38,815 | $42.35 | $1.64M | 1,849,570 | SEC↗ |
| RPRX Royalty Pharma plc | S Sale | 2021-11-17 | 2021-11-18 | 69,233 | $42.35 | $2.93M | 500,549 | SEC↗ |
| RPRX Royalty Pharma plc | S Sale | 2021-11-17 | 2021-11-18 | 62,435 | $42.39 | $2.65M | 622,398 | SEC↗ |
| RPRX Royalty Pharma plc | J Other | 2021-11-16 | 2021-11-18 | 4,674 | — | $0 | 636,060 | SEC↗ |
| RPRX Royalty Pharma plc | J Other | 2021-11-16 | 2021-11-18 | 612,668 | — | $0 | 1,146,986 | SEC↗ |
| RPRX Royalty Pharma plc | J Other | 2021-11-16 | 2021-11-18 | 1,028,973 | — | $0 | 1,888,385 | SEC↗ |
| RPRX Royalty Pharma plc | J Other | 2021-11-16 | 2021-11-18 | 219,710 | — | $0 | 569,782 | SEC↗ |
| RPRX Royalty Pharma plc | S Sale | 2021-11-16 | 2021-11-18 | 12,565 | $42.01 | $527.9K | 684,833 | SEC↗ |
| RPRX Royalty Pharma plc | J Other | 2021-11-16 | 2021-11-18 | 61,338 | — | $0 | 697,398 | SEC↗ |
| ITCI Intra-Cellular Therapies, | A Award | 2021-09-30 | 2021-10-04 | 422 | $37.28 | $15.7K | 76,515 | SEC↗ |
| RPRX Royalty Pharma plc | J Other | 2021-09-29 | 2021-09-30 | 109,814 | — | $0 | 789,492 | SEC↗ |
| RPRX Royalty Pharma plc | S Sale | 2021-09-29 | 2021-09-30 | 34,604 | $36.31 | $1.26M | 899,306 | SEC↗ |
| RPRX Royalty Pharma plc | J Other | 2021-09-29 | 2021-09-30 | 8,641 | — | $0 | 631,386 | SEC↗ |
| RPRX Royalty Pharma plc | J Other | 2021-09-29 | 2021-09-30 | 5,299 | — | $0 | 622,745 | SEC↗ |
| RPRX Royalty Pharma plc | S Sale | 2021-09-29 | 2021-09-30 | 7,000 | $36.67 | $256.7K | 2,074,540 | SEC↗ |
| RPRX Royalty Pharma plc | S Sale | 2021-09-29 | 2021-09-30 | 24,648 | $36.50 | $899.7K | 615,112 | SEC↗ |
| RPRX Royalty Pharma plc | J Other | 2021-09-29 | 2021-09-30 | 314,886 | — | $0 | 1,759,654 | SEC↗ |
| RPRX Royalty Pharma plc | S Sale | 2021-09-29 | 2021-09-30 | 22,173 | $36.31 | $805.1K | 3,429,085 | SEC↗ |
| RPRX Royalty Pharma plc | J Other | 2021-09-29 | 2021-09-30 | 511,727 | — | $0 | 2,917,358 | SEC↗ |
| RPRX Royalty Pharma plc | J Other | 2021-09-29 | 2021-09-30 | 2,334 | — | $0 | 617,446 | SEC↗ |
| RPRX Royalty Pharma plc | S Sale | 2021-09-28 | 2021-09-30 | 40,000 | $36.75 | $1.47M | 639,760 | SEC↗ |
| RPRX Royalty Pharma plc | G Gift deriv | 2021-09-10 | 2021-09-30 | 7,692 | — | $0 | 534,059 | SEC↗ |
| ITCI Intra-Cellular Therapies, | A Award | 2021-06-30 | 2021-07-02 | 385 | $40.82 | $15.7K | 76,093 | SEC↗ |
| RPRX Royalty Pharma plc | S Sale | 2021-06-29 | 2021-06-29 | 1,200 | $42.01 | $50.4K | 3,931,058 | SEC↗ |
| RPRX Royalty Pharma plc | S Sale | 2021-06-29 | 2021-06-29 | 479,800 | $41.26 | $19.80M | 3,451,258 | SEC↗ |
| RPRX Royalty Pharma plc | S Sale | 2021-06-28 | 2021-06-29 | 167,448 | $42.11 | $7.05M | 3,932,258 | SEC↗ |
| RPRX Royalty Pharma plc | S Sale | 2021-06-25 | 2021-06-29 | 487,364 | $42.69 | $20.81M | 4,099,706 | SEC↗ |
| RPRX Royalty Pharma plc | S Sale | 2021-06-25 | 2021-06-29 | 179,100 | $42.81 | $7.67M | 933,910 | SEC↗ |
| ITCI Intra-Cellular Therapies, | A Award deriv | 2021-06-21 | 2021-06-22 | 20,000 | — | $0 | 20,000 | SEC↗ |
| RPRX Royalty Pharma plc | S Sale | 2021-06-07 | 2021-06-08 | 273,650 | $45.26 | $12.39M | 2,081,540 | SEC↗ |
| ITCI Intra-Cellular Therapies, | M Exercise deriv | 2021-05-27 | 2021-06-04 | 13,767 | — | $0 | 0 | SEC↗ |
| ITCI Intra-Cellular Therapies, | M Exercise | 2021-05-27 | 2021-06-04 | 13,767 | — | $0 | 75,708 | SEC↗ |
| FGEN FIBROGEN INC | A Award deriv | 2021-05-26 | 2021-05-28 | 7,800 | — | $0 | 7,800 | SEC↗ |
| FGEN FIBROGEN INC | A Award | 2021-05-26 | 2021-05-28 | 4,700 | — | $0 | 395,750 | SEC↗ |
| RPRX Royalty Pharma plc | C Conversion deriv | 2021-05-07 | 2021-05-11 | 235,519 | — | $0 | 0 | SEC↗ |
| RPRX Royalty Pharma plc | C Conversion deriv | 2021-05-07 | 2021-05-11 | 67,976 | — | $0 | 541,751 | SEC↗ |
| RPRX Royalty Pharma plc | C Conversion | 2021-05-07 | 2021-05-11 | 2,355,190 | — | $0 | 2,355,190 | SEC↗ |
| RPRX Royalty Pharma plc | C Conversion | 2021-05-07 | 2021-05-11 | 679,760 | — | $0 | 679,760 | SEC↗ |
| ITCI Intra-Cellular Therapies, | A Award | 2021-03-31 | 2021-04-02 | 464 | $33.93 | $15.7K | 61,941 | SEC↗ |
| ITCI Intra-Cellular Therapies, | A Award | 2020-12-31 | 2021-01-05 | 495 | $31.80 | $15.7K | 61,477 | SEC↗ |
| RPRX Royalty Pharma plc | C Conversion deriv | 2020-10-20 | 2020-10-22 | 46,320 | — | $0 | 191,681 | SEC↗ |
| RPRX Royalty Pharma plc | S Sale | 2020-10-20 | 2020-10-22 | 463,200 | $42.00 | $19.45M | 0 | SEC↗ |
| RPRX Royalty Pharma plc | C Conversion | 2020-10-20 | 2020-10-22 | 463,200 | — | $0 | 463,200 | SEC↗ |
| RPRX Royalty Pharma plc | S Sale | 2020-10-20 | 2020-10-23 | 463,200 | $42.00 | $19.45M | 0 | SEC↗ |
| ITCI Intra-Cellular Therapies, | A Award | 2020-09-30 | 2020-10-02 | 613 | $25.66 | $15.7K | 60,982 | SEC↗ |
| ITCI Intra-Cellular Therapies, | A Award | 2020-06-30 | 2020-07-02 | 613 | $25.67 | $15.7K | 60,369 | SEC↗ |
| ITCI Intra-Cellular Therapies, | M Exercise deriv | 2020-06-25 | 2020-06-26 | 14,005 | — | $0 | 0 | SEC↗ |
| ITCI Intra-Cellular Therapies, | M Exercise | 2020-06-25 | 2020-06-26 | 14,005 | — | $0 | 59,756 | SEC↗ |
| RPRX Royalty Pharma plc | C Conversion deriv | 2020-06-18 | 2021-02-26 | 458,707 | — | $0 | 0 | SEC↗ |
| RPRX Royalty Pharma plc | C Conversion deriv | 2020-06-18 | 2021-02-26 | 111,301 | — | $0 | 0 | SEC↗ |
| RPRX Royalty Pharma plc | C Conversion | 2020-06-18 | 2021-02-26 | 4,587,070 | — | $0 | 4,587,070 | SEC↗ |
| RPRX Royalty Pharma plc | C Conversion | 2020-06-18 | 2021-02-26 | 1,113,010 | — | $0 | 1,113,010 | SEC↗ |
| RPRX Royalty Pharma plc | P Buy | 2020-06-18 | 2020-06-23 | 15,000 | $28.00 | $420.0K | 15,000 | SEC↗ |
| RPRX Royalty Pharma plc | A Award deriv | 2020-06-15 | 2020-06-23 | 119,982 | — | $0 | 119,982 | SEC↗ |
| RPRX Royalty Pharma plc | A Award deriv | 2020-06-15 | 2020-06-23 | 494,485 | — | $0 | 494,485 | SEC↗ |
| RPRX Royalty Pharma plc | A Award deriv | 2020-06-15 | 2020-06-23 | 253,889 | — | $0 | 253,889 | SEC↗ |
| RPRX Royalty Pharma plc | A Award deriv | 2020-06-15 | 2020-06-23 | 435,267 | — | $0 | 435,267 | SEC↗ |
| RPRX Royalty Pharma plc | A Award deriv | 2020-06-15 | 2020-06-23 | 238,001 | — | $0 | 238,001 | SEC↗ |
| FGEN FIBROGEN INC | A Award deriv | 2020-06-04 | 2020-06-08 | 7,800 | — | $0 | 7,800 | SEC↗ |
| FGEN FIBROGEN INC | A Award | 2020-06-04 | 2020-06-08 | 4,700 | — | $0 | 391,050 | SEC↗ |
| ITCI Intra-Cellular Therapies, | A Award deriv | 2020-05-27 | 2020-05-28 | 13,767 | — | $0 | 13,767 | SEC↗ |
| ITCI Intra-Cellular Therapies, | A Award | 2020-03-31 | 2020-04-02 | 1,024 | $15.37 | $15.7K | 45,751 | SEC↗ |
| ITCI Intra-Cellular Therapies, | A Award | 2019-12-31 | 2020-01-03 | 422 | $34.31 | $14.5K | 44,727 | SEC↗ |
| ITCI Intra-Cellular Therapies, | A Award | 2019-09-30 | 2019-10-02 | 1,941 | $7.47 | $14.5K | 44,305 | SEC↗ |
| ITCI Intra-Cellular Therapies, | A Award | 2019-06-28 | 2019-07-02 | 1,117 | $12.98 | $14.5K | 42,364 | SEC↗ |
| ITCI Intra-Cellular Therapies, | A Award deriv | 2019-06-25 | 2019-06-26 | 14,005 | — | $0 | 14,005 | SEC↗ |
| ITCI Intra-Cellular Therapies, | M Exercise deriv | 2019-06-18 | 2024-10-15 | 14,189 | — | $0 | 0 | SEC↗ |
| ITCI Intra-Cellular Therapies, | M Exercise | 2019-06-18 | 2024-10-15 | 14,189 | — | $0 | 131,297 | SEC↗ |
| FGEN FIBROGEN INC | A Award deriv | 2019-06-05 | 2019-06-07 | 7,800 | — | $0 | 7,800 | SEC↗ |
| FGEN FIBROGEN INC | A Award | 2019-06-05 | 2019-06-07 | 4,700 | — | $0 | 386,350 | SEC↗ |
| ITCI Intra-Cellular Therapies, | A Award | 2019-03-31 | 2019-04-02 | 1,190 | $12.18 | $14.5K | 41,247 | SEC↗ |
| ITCI Intra-Cellular Therapies, | A Award | 2018-12-31 | 2019-01-03 | 1,273 | $11.39 | $14.5K | 40,057 | SEC↗ |
| ITCI Intra-Cellular Therapies, | A Award | 2018-09-30 | 2018-10-02 | 668 | $21.70 | $14.5K | 38,784 | SEC↗ |
| FGEN FIBROGEN INC | G Gift | 2018-09-27 | 2018-09-28 | 1,250 | — | $0 | 381,650 | SEC↗ |
| ITCI Intra-Cellular Therapies, | A Award | 2018-06-29 | 2018-07-03 | 820 | $17.67 | $14.5K | 38,116 | SEC↗ |
| ITCI Intra-Cellular Therapies, | A Award deriv | 2018-06-18 | 2018-06-20 | 14,189 | — | $0 | 14,189 | SEC↗ |
| FGEN FIBROGEN INC | A Award deriv | 2018-06-05 | 2018-06-07 | 6,000 | — | $0 | 6,000 | SEC↗ |
| FGEN FIBROGEN INC | A Award | 2018-06-05 | 2018-06-07 | 3,700 | — | $0 | 382,900 | SEC↗ |
| ITCI Intra-Cellular Therapies, | A Award | 2018-03-30 | 2018-04-03 | 688 | $21.05 | $14.5K | 37,296 | SEC↗ |
| FGEN FIBROGEN INC | S Sale | 2018-03-13 | 2018-03-14 | 5,402 | $53.07 | $286.7K | 386,200 | SEC↗ |
| FGEN FIBROGEN INC | S Sale | 2018-03-13 | 2018-03-14 | 4,382 | $54.90 | $240.6K | 381,818 | SEC↗ |
| FGEN FIBROGEN INC | S Sale | 2018-03-13 | 2018-03-14 | 2,618 | $55.19 | $144.5K | 379,200 | SEC↗ |
| FGEN FIBROGEN INC | S Sale | 2018-03-12 | 2018-03-14 | 19,693 | $54.98 | $1.08M | 391,602 | SEC↗ |
| FGEN FIBROGEN INC | S Sale | 2018-03-09 | 2018-03-09 | 22,905 | $55.75 | $1.28M | 411,295 | SEC↗ |
| ITCI Intra-Cellular Therapies, | P Buy | 2017-12-29 | 2018-01-03 | 1,001 | $14.48 | $14.5K | 36,608 | SEC↗ |
| ITCI Intra-Cellular Therapies, | A Award | 2017-12-29 | 2018-01-03 | 1,001 | $14.48 | $14.5K | 36,608 | SEC↗ |
| ITCI Intra-Cellular Therapies, | A Award | 2017-09-29 | 2017-10-03 | 918 | — | $0 | 35,607 | SEC↗ |
| FGEN FIBROGEN INC | S Sale | 2017-09-13 | 2017-09-15 | 25,000 | $51.92 | $1.30M | 435,200 | SEC↗ |
| ITCI Intra-Cellular Therapies, | A Award | 2017-06-30 | 2017-07-05 | 1,167 | — | $0 | 34,689 | SEC↗ |
| ITCI Intra-Cellular Therapies, | A Award deriv | 2017-06-27 | 2017-06-29 | 20,000 | — | $0 | 20,000 | SEC↗ |
| FGEN FIBROGEN INC | A Award deriv | 2017-06-07 | 2017-06-09 | 12,000 | — | $0 | 12,000 | SEC↗ |
| ITCI Intra-Cellular Therapies, | A Award | 2017-03-31 | 2017-04-04 | 892 | — | $0 | 33,522 | SEC↗ |
| ITCI Intra-Cellular Therapies, | A Award | 2016-12-30 | 2017-01-03 | 960 | — | $0 | 32,630 | SEC↗ |
| FGEN FIBROGEN INC | S Sale | 2016-12-16 | 2016-12-16 | 20,000 | $20.87 | $417.4K | 460,200 | SEC↗ |
| ITCI Intra-Cellular Therapies, | A Award | 2016-09-30 | 2016-10-04 | 951 | — | $0 | 31,670 | SEC↗ |
| ITCI Intra-Cellular Therapies, | A Award | 2016-06-30 | 2016-07-05 | 373 | — | $0 | 30,719 | SEC↗ |
| ITCI Intra-Cellular Therapies, | A Award deriv | 2016-06-14 | 2016-06-15 | 20,000 | — | $0 | 20,000 | SEC↗ |
| FGEN FIBROGEN INC | A Award deriv | 2016-06-08 | 2016-06-10 | 12,000 | — | $0 | 12,000 | SEC↗ |
| ITCI Intra-Cellular Therapies, | A Award | 2016-03-31 | 2016-04-04 | 382 | — | $0 | 16,061 | SEC↗ |
| ITCI Intra-Cellular Therapies, | A Award | 2015-12-31 | 2016-01-05 | 197 | $53.79 | $10.6K | 15,679 | SEC↗ |
| ITCI Intra-Cellular Therapies, | A Award | 2015-09-30 | 2015-10-02 | 265 | — | $0 | 15,482 | SEC↗ |
| FGEN FIBROGEN INC | S Sale | 2015-09-14 | 2015-09-15 | 25,571 | $27.56 | $704.7K | 480,200 | SEC↗ |
| FGEN FIBROGEN INC | S Sale | 2015-09-11 | 2015-09-15 | 100 | $29.52 | $3.0K | 505,771 | SEC↗ |
| FGEN FIBROGEN INC | S Sale | 2015-09-11 | 2015-09-15 | 4,329 | $28.13 | $121.8K | 505,871 | SEC↗ |
| FGEN FIBROGEN INC | S Sale | 2015-09-11 | 2015-09-15 | 20,000 | $27.56 | $551.2K | 510,200 | SEC↗ |
| ITCI Intra-Cellular Therapies, | A Award | 2015-06-30 | 2015-07-02 | 332 | — | $0 | 15,217 | SEC↗ |
| ITCI Intra-Cellular Therapies, | A Award deriv | 2015-06-16 | 2015-06-22 | 20,000 | — | $0 | 20,000 | SEC↗ |
| FGEN FIBROGEN INC | A Award deriv | 2015-06-03 | 2015-06-05 | 12,000 | — | $0 | 12,000 | SEC↗ |
| ITCI Intra-Cellular Therapies, | A Award | 2015-03-31 | 2015-04-02 | 444 | — | $0 | 14,885 | SEC↗ |
| ITCI Intra-Cellular Therapies, | A Award | 2014-12-31 | 2015-01-05 | 601 | — | $0 | 14,441 | SEC↗ |
| FGEN FIBROGEN INC | C Conversion deriv | 2014-11-19 | 2014-11-21 | 100,000 | — | $0 | 0 | SEC↗ |
| FGEN FIBROGEN INC | C Conversion deriv | 2014-11-19 | 2014-11-21 | 225,000 | — | $0 | 0 | SEC↗ |
| FGEN FIBROGEN INC | C Conversion deriv | 2014-11-19 | 2014-11-21 | 150,177 | — | $0 | 0 | SEC↗ |
| FGEN FIBROGEN INC | C Conversion deriv | 2014-11-19 | 2014-11-21 | 334,074 | — | $0 | 0 | SEC↗ |
| FGEN FIBROGEN INC | C Conversion deriv | 2014-11-19 | 2014-11-21 | 50,000 | — | $0 | 0 | SEC↗ |
| FGEN FIBROGEN INC | C Conversion | 2014-11-19 | 2014-11-21 | 233,699 | — | $0 | 605,713 | SEC↗ |
| FGEN FIBROGEN INC | C Conversion | 2014-11-19 | 2014-11-21 | 110,000 | — | $0 | 530,200 | SEC↗ |
| FGEN FIBROGEN INC | A Award deriv | 2014-11-13 | 2014-11-17 | 12,000 | — | $0 | 12,000 | SEC↗ |
| ITCI Intra-Cellular Therapies, | A Award | 2014-09-30 | 2014-10-02 | 774 | — | $0 | 13,840 | SEC↗ |
| ITCI Intra-Cellular Therapies, | A Award deriv | 2014-06-30 | 2014-07-02 | 20,000 | — | $0 | 20,000 | SEC↗ |
| ITCI Intra-Cellular Therapies, | A Award | 2014-06-30 | 2014-07-02 | 1,260 | — | $0 | 13,066 | SEC↗ |
| ITCI Intra-Cellular Therapies, | A Award deriv | 2014-03-21 | 2014-03-24 | 20,000 | — | $0 | 20,000 | SEC↗ |
| ITCI Intra-Cellular Therapies, | P Buy | 2014-02-05 | 2016-04-20 | 14,286 | $17.50 | $250.0K | 226,670 | SEC↗ |
| ITCI Intra-Cellular Therapies, | P Buy | 2014-02-05 | 2016-04-20 | 14,285 | $17.50 | $250.0K | 26,091 | SEC↗ |
| ITCI Intra-Cellular Therapies, | P Buy | 2014-02-05 | 2014-02-05 | 28,571 | $17.50 | $500.0K | 240,955 | SEC↗ |
| RPRX Royalty Pharma plc | S Sale | 2002-12-12 | 2022-12-13 | 40,010 | $41.98 | $1.68M | 96,712 | SEC↗ |